Open House Discount Agreements Amifampridin
Original notice title
Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Amifampridin, ATC N07XX05
Opportunity Score
Why this score?
Opportunity
40 / 100
Complexity
20 / 100
Risk factors
No guaranteed value; actual revenue depends on market uptake and may be low.
Submission process is specific: use communication area (not offer area) and strictly follow format (electronic qualifie...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Overview
Strong opportunityKey Facts
- Framework procurement
- Supplies contract
- 1 lot
- Duration until Aug 2027
- Enter into non-exclusive discount agreements for the pharmaceutical active substance Amifampridin (ATC N07XX05) with AOK Bayern.
- Agreements are based on a standardized, non-negotiable contract template.
Show full summary
This notice describes an open house model (not a competitive procurement) for non-exclusive pharmaceutical discount agreements on the active substance Amifampridin (ATC N07XX05) by AOK Bayern. Any eligible pharmaceutical company can join at any time during the contract term. The agreement period is from 01.09.2025 to 31.08.2027, with contracts possible until 03.07.2027. There is no selection process; all qualifying companies that submit the required documents will be accepted. No estimated value is provided. The tender is open only to pharmaceutical companies, and all documents must be in German.
Risks
No guaranteed value; actual revenue depends on market uptake and may be low.
Submission process is specific: use communication area (not offer area) and strictly follow format (electronic qualifie...
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
Technical
- Proof of authorization (commercial register extract or power of attorney) for signatories.
Eligibility
- Only pharmaceutical companies are eligible to participate.
Administrative
- Submission of a completed and signed contract, signed annex 'Festlegung der vertragsgegenständlichen Arzneimittel', and signed declaration of reliability.
Requirements may be incomplete.
Award Criteria
Lot 1
Buyer
Location
München, DEU
Website
Buyer profile
Identifier
DE811695320
Activity
Health
Lots (1)
LOT-0001
Open House Discount Agreements Amifampridin
Open house model for discount agreements on Amifampridin (ATC N07XX05). Any qualifying pharmaceutical company may join. Contracts start on the first of the month following submission (if submitted by the 3rd). No competitive selection; all eligible participants are accepted. Contract duration 01.09.2025-31.08.2027.
Location
Duration
Category
Award Criteria
Deadline
Award details
Siehe kurze Beschreibung ACHTUNG: Die Vertragsunterlagen sind zwingend über den Kommunikationsbereich im Vergabeportal www.dtvp.de einzureichen und keinesfalls über den Angebotsbereich! BITTE BEACHTEN SIE: Die FRIST für einen Vertragsschluss zum nächsten Monatsersten endet jeweils am DRITTEN des Vormonats.
Value note
Show original TED data
Original lot title
Open house Arzneimittelrabattverträge Amifampridin, ATC N07XX05
Original TED description
Siehe kurze Beschreibung ACHTUNG: Die Vertragsunterlagen sind zwingend über den Kommunikationsbereich im Vergabeportal www.dtvp.de einzureichen und keinesfalls über den Angebotsbereich! BITTE BEACHTEN SIE: Die FRIST für einen Vertragsschluss zum nächsten Monatsersten endet jeweils am DRITTEN des Vormonats.
Procurement Details
- Publication date
- 13 Jul 2025
- Languages
- German
Reference metadata
- Legal basis
- 32014L0024
Reference IDs
- Tender ID
- 456857-2025
Documents (2)
Similar tenders
Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)
Denmark – Pharmaceutical products – Amgros 2027 1.1170.a
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)
Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta
Opportunity Score
Why this score?
Opportunity
40 / 100
Complexity
20 / 100
Risk factors
No guaranteed value; actual revenue depends on market uptake and may be low.
Submission process is specific: use communication area (not offer area) and strictly follow format (electronic qualifie...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications